NCT03467867View on ClinicalTrials.gov

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Venetoclax

Venetoclax will be administered as described in the reporting arm.

DRUG

Rituximab

Rituximab (IV) will be administered as described in the reporting arm.

DRUG

Rituximab/Hyaluronidase Human

Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.

Trial Locations (2)

20007

Georgetown University Medical Center, Washington D.C.

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

Hackensack Meridian Health

OTHER

lead

Georgetown University

OTHER